Prescription Drugs · Cardiometabolic Therapeutics
Cytokinetics revenue, results and funding
Cytokinetics filed revenue of $88M for 2025.
Data updated Nov 15, 2026 · Back to the company report
$88MRevenue, 2025
−$785MNet income, 2025
Results by year
| Year | Revenue | Net income | Total assets |
|---|---|---|---|
| 2025 | $88M | −$785M | $1.4B |
| 2024 | $18.5M | −$589.5M | $1.4B |
| 2023 | $7.5M | −$526.2M | $824.3M |
| 2022 | $94.6M | −$389M | $1B |
| 2021 | $70.4M | −$215.3M | $841.3M |
| 2020 | $55.8M | −$127.3M | $533.8M |
| 2019 | $26.9M | −$121.7M | $289.8M |
| 2018 | $31.5M | −$106.3M | $211.2M |
| 2017 | $13.4M | −$127.8M | $294.8M |
| 2016 | $106.4M | $16.5M | $170.1M |
| 2015 | $28.7M | −$37.5M | $115.2M |
| 2014 | $46.9M | −$14.6M | $133M |
| 2013 | $30.6M | −$33.7M | $83.2M |
| 2012 | $7.6M | −$40.4M | $77.6M |
| 2011 | $4M | −$47.9M | $52.8M |
Sources: SEC
How to cite
Cytokinetics, Financials. Alion, Nov 15, 2026. https://alion.io/company/cytokinetics/financials